| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 10, 2009
Accepted on March 6, 2009
From the Department of Pathobiology and Laboratory Medicine (W.S.D., R.A.G.D.S.), University of Cincinnati, Ohio; Université Pierre et Marie Curie-Paris 6 (S.C., M.J.C., A.K.), Paris, France; AP-HP (S.C., M.J.C., A.K.), Groupe hospitalier Pitié-Salpétrière, Paris, France; INSERM (S.C., M.J.C., A.K.), Dyslipoproteinemia and Atherosclerosis Research Unit 551, Paris France; and the Institute for Translational Medicine and Therapeutics (W.R.L.), University of Pennsylvania, Philadelphia.
* To whom correspondence should be addressed. E-mail: Sean.Davidson{at}UC.edu.
Objective—Recent proteomic studies have identified multiple proteins that coisolate with human HDL. We hypothesized that distinct clusters of protein components may distinguish between physicochemically-defined subpopulations of HDL particles, and that such clusters may exert specific biological function(s).
Methods and Results—We investigated the distribution of proteins across 5 physicochemically-defined particle subpopulations of normolipidemic human HDL (HDL2b, 2a, 3a, 3b, 3c) fractionated by isopycnic density gradient ultracentrifugation. Liquid chromatography/electrospray mass spectrometry identified a total of 28 distinct HDL-associated proteins. Using an abundance pattern analysis of peptide counts across the HDL subfractions, these proteins could be grouped into 5 distinct classes. A more in-depth correlational network analysis suggested the existence of distinct protein clusters, particularly in the dense HDL3 particles. Levels of specific HDL proteins, primarily apoL-I, PON1, and PON3, correlated with the potent capacity of HDL3 to protect LDL from oxidation.
Conclusions—These findings suggest that HDL is composed of distinct particles containing unique (apolipo)protein complements. Such subspeciation forms a potential basis for understanding the numerous observed functions of HDL. Further work using additional separation techniques will be required to define these species in more detail.
This article has been cited by other articles:
![]() |
A. Zerrad-Saadi, P. Therond, S. Chantepie, M. Couturier, K.-A. Rye, M. J. Chapman, and A. Kontush HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2169 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., October 12, 2009; (2009) ehp399v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Hoofnagle and J. W. Heinecke Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins J. Lipid Res., October 1, 2009; 50(10): 1967 - 1975. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Superko Cardiovascular event risk: high-density lipoprotein and paraoxonase. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1246 - 1248. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |